临床肿瘤学杂志 ›› 2023, Vol. 28 ›› Issue (02): 120-.

• • 上一篇    

miR-204启动子甲基化作为结直肠癌表观遗传生物标志物的临床研究

  

  1. 610500  成都   成都市新都区人民医院病理科

  • 收稿日期:2022-01-07 修回日期:2022-10-16 出版日期:2023-02-28 发布日期:2023-04-04

Clinical study on methylation of miR-204 promoter as an epigenetic biomarker of colorectal cancer

  1.  Department of Pathology, Xindu District Peoples Hospital of Chengdu, Chengdu 610500,China
  • Received:2022-01-07 Revised:2022-10-16 Online:2023-02-28 Published:2023-04-04

摘要:

【摘要】目的探讨miR-204启动子甲基化在结直肠癌(CRC)中的临床意义。方法收集2018年1月至2020年3月于我院就诊的69例CRC患者血浆样本、肿瘤组织标本和癌旁正常结肠黏膜组织标本;另外招募68例健康志愿者作为正常对照组,采集血浆样本。使用肿瘤基因图谱计划(TCGA)数据库与基因芯片数据(Methyl450K)分析肿瘤和正常组织中识别的CpG位点的甲基化水平。采用定量甲基化特异性PCR法(qMSP)和实时荧光定量PCR法(qPCR)检测样本中miR-204启动子区甲基化状态和基因表达量。结果TCGA数据表明miR-204表达与宿主基因TRPM3的表达协调下调,并确定了miR-204启动子周围的两个CpG岛。与癌旁组织比较,CRC组织中miR-204启动子甲基化参考百分比(PMR)升高[1.78(0.35,16.61)vs. 1.51(0.45,2.98),P<0.001],且与miR-204表达量呈负相关(r=-0.324,P=0.007),与DNA甲基转移酶1 mRNA呈正相关(r=0.502,P<0.001)。此外,与正常对照组比较,CRC患者血浆cfDNA中miR-204启动子PMR显著升高[6.57(0.76,12.45)vs. 1.60(0.59,3.4),P=0.015],并且与CRC组织miR-204启动子PMR呈正相关(r=0.418,P<0.001)。血浆cfDNA中miR-204启动子PMR用于CRC的诊断的受试者工作特征曲线下面积为0.701(95%CI:0.610~0.791),灵敏度和特异度分别为56.5%和94.1%。此外,进一步依据临床分期、分化程度等进行分层分析,并未观察到miR-204启动子超甲基化与CRC患者主要临床特征的关系(P>0.05)。结论miR-204启动子甲基化与CRC显著相关,并且血浆cfDNA中miR-204启动子甲基化状态或可作为CRC诊断和监测的潜在生物标记物。

关键词: 结直肠癌, 甲基化, miR-204, 表观遗传学

Abstract:

【Abstract】Objective  To investigate the clinical significance of miR-204 promoter methylation in colorectal cancer (CRC). Methods From January 2018 to March 2020,the blood samples, tumor tissue samples and paracarcinoma normal colon mucosal tissue samples were collected from 69 CRC patients admitted to the department of gastroenterology of our hospital. Another 68 healthy volunteers were recruited as the normal control group. The plasma samples were collected. Methylation levels of CpG sites identified in tumor and normal tissue were analyzed using the Tumor Gene Atlas Project (TCGA) database and gene-on-a-chip data (Methyl450K). The gene expression and promoter methylation status of miR-204 were detected by quantitative methylation-specific PCR (qMSP) and quantitative real-time PCR (qPCR). Results The TCGA data indicated that the expression of miR-204 was coordinately down-regulated with the expression of host gene TRPM3, and two CpG islands around the miR-204 promoter were identified. Compared with the paracancer tissues, the miR-204 promoter methylation reference percentage (PMR) was increased in CRC tissues[1.78 (0.35, 16.61) vs. 1.51 (0.45, 2.98), P<0.001]. And the methylation level of miR-204 promoter was negatively correlated with the expression level of miR-204 (r=-0.324, P=0.007), and positively correlated with DNA methyltransferase 1 mRNA (r=0.502, P<0.001). Moreover, compared with the normal control group, the PMR of miR-204 promoter was significantly higher in plasma cfDNA of CRC patients[6.57 (0.76, 12.45) vs. 1.60 (0.59, 3.4), P=0.015]. And PMR of miR-204 promoter in plasma cfDNA of CRC patients was positively correlated with PMR of miR-204 promoter in CRC tissues (r=0.418, P<0.001).The area under receiver operating characteristic curve of PMR of miR-204 promoter in plasma cfDNA for CRC diagnosis was 0.701 (95%CI: 0.610-0.791), the sensitivity and specificity were 56.5% and 94.1%. In addition, further stratified analysis was conducted according to clinical stage and differentiation degree, there was no significant correlation between the hypermethylation of miR-204 promoter and the main clinical characteristics of CRC patients (P>0.05). Conclusion miR-204 promoter methylation is significantly correlated with CRC, and the status of miR-204 promoter methylation in plasma cfDNA may be used as potential biomarkers for CRC diagnosis and monitoring.

Key words: Colorectal cancer, Methylation, miR-204, Epigenetics

中图分类号: 

  • R735.3
[1] 王新伟, 吕柯, 宋展, 钱国武, 于思筠.  ADAM15通过激活EGFR促进结直肠癌细胞的转移侵袭[J]. 临床肿瘤学杂志, 2018, 23(10): 881-885.
[2] 元建华, 李建旺, 毛山山, 崔荣花, 王美清.  Ⅰ~Ⅲ期结直肠癌中Livin的表达及其临床意义[J]. 临床肿瘤学杂志, 2018, 23(10): 910-914.
[3] 蒋文, 王礼学, 丁怀银, 郑勤, 徐瀚峰, 杨觅, 张全安.  循环肿瘤细胞监测在结直肠癌肝转移微波消融治疗中临床价值的评估[J]. 临床肿瘤学杂志, 2018, 23(10): 925-930.
[4] 何治军, 吴连宝, 韩江.  加速康复外科在结直肠癌围手术期的效果观察[J]. 临床肿瘤学杂志, 2018, 23(10): 931-936.
[5] 孟存英, 安 太, 史盛梅, 张春莉, 刘 琰, 袁东红, 马 莹, 刘鹏飞. DCLK1、Bmi-1在结直肠癌中的表达及临床意义[J]. 临床肿瘤学杂志, 2018, 23(5): 419-423.
[6] 张德志, 张 宇, 朱少功. VEGFR2基因rs10013228多态性对R0切除结直肠癌患者预后的影响[J]. 临床肿瘤学杂志, 2018, 23(5): 424-428.
[7] 王珊珊, 汪海岩, 武 斌, 赵利红, 李 栋, 谢 彦. 甲磺酸阿帕替尼在多线治疗失败的晚期结肠癌中的近期临床疗效与安全性观察[J]. 临床肿瘤学杂志, 2018, 23(5): 453-457.
[8] 杨野梵, 马中华 综述, 王科明 审校. 长链非编码RNA调控结直肠癌耐药的研究进展[J]. 临床肿瘤学杂志, 2018, 23(5): 458-462.
[9] 姚波, 路 娜. 放疗在同步转移直肠癌中的应用价值[J]. 临床肿瘤学杂志, 2018, 23(5): 463-466.
[10] 李 进,曹 君. 大肠癌单克隆抗体治疗新进展[J]. 临床肿瘤学杂志, 2009, 14(1): 1-.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!